Sawai Group Holdings Co., Ltd.

Sawai Group Holdings Co., Ltd., together with its associated companies, focuses on the entire lifecycle of generic medications, from their initial research and development to manufacturing and commercialization. The company's primary operational markets are Japan and the United States. Its diverse portfolio includes generic drugs in numerous dosage forms, such as traditional tablets, orally dissolving tablets, capsules, granular preparations, injectable solutions, transdermal patches, ophthalmic and nasal drops, and syrups. These products address a wide array of medical conditions, encompassing therapeutic areas like cardiovascular health, gastrointestinal disorders, central nervous system ailments, allergies, various cancers, infectious diseases, and hormonal therapies. Key offerings from their extensive product line include atorvastatin, lansoprazole, oseltamivir, pregabalin, and fexofenadine hydrochloride. In Japan, Sawai distributes its generic pharmaceutical products through multiple channels: directly to medical facilities such as hospitals, clinics, and dispensing pharmacies, and indirectly through distributors, retail outlets, and other pharmaceutical manufacturers. For the U.S. market, the company supplies its products to pharmaceutical wholesalers. Sawai Group Holdings Co., Ltd. was established in 1929 and is based in Osaka, Japan.

業界

Drug Manufacturers - Specialty & Generic

セクター

Healthcare

本社

JP

最高経営責任者（CEO）

Mitsuo Sawai

上場以来

2021年4月1日

従業員

3,630